選択的TYK2阻害、出生前細胞診断、およびバイオマーカー誘導免疫療法:精密医療の拡大
Mahmoud A Elkhalifa1, Robert B Kargbo2
1University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323, United States.
Abstract:
Recent innovations showcase the power of selectivity in precision medicine. Brain-penetrant TYK2 inhibitors target autoimmune and neuroinflammatory disease, fetal cell diagnostics improve prenatal screening, and biomarker signatures refine checkpoint immunotherapy. Together, these advances highlight how molecular, cellular, and patient-level selectivity drives therapeutic precision across neurology, oncology, immunology, and reproductive health, reshaping diagnostics and treatment strategies from early development through complex disease.
関連する概念動画
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...


